Pulmonary surfactant market

Pulmonary Surfactant Market, by Type (Synthetic Pulmonary Surfactant,Animal Derived Surfactant), by Drug Type (Poractant alfa, Lucinactant, Calfactant), by Indications (Respiratory Distress Syndrome (RDS), Respiratory Infections, Obstructive lung Diseases, Others(chronic lung disease of prematurity, and surfactant protein-B deficiency)), by Route of Administration (Intratracheal, Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Nov 2022
CMI5324
161 Pages
Excel & Pdf
Biotechnology

Summary

Pulmonary surfactant is a complex mixture of phospholipids and proteins that creates a unique interface separating alveolar gas and liquids at the alveolar cell surface, reducing surface tension, and maintaining lung volumes at end expiration. Reduction of the surface tension at the air–liquid interface is a requirement for respiratory function following birth. Deficiency of pulmonary surfactant causes respiratory failure in premature infants, or infantile respiratory distress syndrome (IRDS). The adequacy of pulmonary surfactant is maintained by unique and highly regulated systems mediating the synthesis, secretion, reutilization, and catabolism of surfactant. Loss or inactivation of pulmonary surfactant later in life occurs in the adult respiratory distress syndrome (ARDS), a significant cause of morbidity and mortality following infection, shock, or trauma. Mutations in genes regulating surfactant homeostasis, including SFTPA, SFTPB, SFTPC, ABCA3, TITF1, and CSF2RA cause acute and/or chronic lung disease in newborn infants, children, and adults. Disorders of GM-CSF signaling inhibit surfactant lipid and protein catabolism by alveolar macrophage causing pulmonary alveolar proteinosis (PAP).

Global pulmonary surfactant market size was valued at US$ 578.7 million in 2022 and is expected to witness a CAGR of 4.50 % over the forecast period (2022 – 2030).

Figure 1.Global Pulmonary Surfactant Market Share (%), by Type, 2022

Pulmonary Surfactant Market-Drivers

Increasing preference of animal derived surfactant for the treatment of respiratory distress syndrome is driving the pulmonary surfactant market growth over the forecast period.

Increasing preference of animal derived surfactant for the treatment of respiratory distress syndrome is driving the pulmonary surfactant market growth over the forecast period. For instance, in May 2021, according to the article published in Archives of Clinical and Medical Case Reports, an open access, peer reviewed Journal, Poractant alfa (Curosurf), significantly reduced the rates of pneumothorax (the presence of air or gas in the cavity between the lungs and the chest wall, causing collapse of the lung) in preterm infants with respiratory distress syndrome. This reduction was more significant in VLBW (very low birth weight) than non-VLBW (very low birth weight) infants.

Furthermore, on April 11, 2022, an article was published in National Center for Biotechnology Information, a branch of the National Institutes of Health, which reported that when animal derived pulmonary surfactant is combined with budesonide, a corticosteroid or steroid, in the treatment of neonatal respiratory distress syndrome can effectively shorten the hospital stay and reduce the time of invasive mechanical ventilation and the incidence of BPD (bronchopulmonary dysplasia). Meanwhile, it does not increase the risk of related complications or death. This approach can be applied clinically.

Pulmonary Surfactant Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 578.7 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	4.50%	2030 Value Projection:	US$ 822.9 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Type: Synthetic Pulmonary Surfactant, Animal Derived Surfactant By Drug Type: Poractant alfa, Lucinactant, Calfactant By Indications: Respiratory Distress Syndrome (RDS), Respiratory Infections, Obstructive lung Diseases, Others(chronic lung disease of prematurity, and surfactant protein-B deficiency) By Route of Administration: Intratracheal, Injectable By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Companies covered:	Boehinger Ingelheim, AbbVie Inc, Chiesi Farmaceutici, ONY Biotech Inc., Lyomark Pharma, Abbott, Aviva Systems Biology Corporation, Windtree Therapeutics, Inc, Tekzima (Noargen), Biomatik, Nanjing Norris Pharm Technology, Reddot Biotech
Growth Drivers:	Increasing preference of animal derived surfactant for the treatment of respiratory distress syndrome Increasing prevalence of respiratory infections are attributing to the highest share of North America market in the global pulmonary surfactant market
Restraints & Challenges:	Increasing number of side effect associated with the pulmonary surfactant drug

Figure 2.Global Pulmonary Surfactant Market Share (%), by Region, 2022

Increasing prevalence of respiratory infections are attributing to the highest share of North America market in the global pulmonary surfactant market.

Increasing prevalence of the respiratory infections in the U.S. is expected to drive market growth over the forecast period. For instance, in June 2021, The Centers for Disease Control and Prevention, a national public health agency of the U.S. stated that each year in the U.S., RSV (Respiratory Syncytial Virus) leads to on average approximately 58,000 hospitalizations with 100-500 deaths among children younger than 5 years old and 177,000 hospitalizations with 14,000 deaths among adults aged 65 years or older. Infants, young children, and older adults with chronic medical conditions are at risk of severe disease from RSV infection

Global Pulmonary Surfactant Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.The sudden outbreak of COVID-19 has bought the world to a standstill.

Increasing research and development between the key market players of pulmonary surfactant market during COVID-19 pandemic is expected to drive the market growth over the forecast period. For instance, on March 22, 2022, Windtree Therapeutics, Inc., a biotechnology company multiple late-stage interventions for acute cardiovascular and pulmonary disorders, announced results from its Phase 2 study of lucinactant (KL4 surfactant) for patients with severe COVID-19 associated acute respiratory distress syndrome (ARDS) and lung injury. The objective for the study was that the SARS-CoV-2 virus causing COVID-19 uses the angiotensin-converting enzyme 2 (ACE2) receptor for entry into host cells. The Phase 2 trial was designed to assess feasibility, safety, and tolerability of administration of reconstituted lyophilized lucinactant in these critically ill patients.

Global Pulmonary Surfactant Market: Key Developments

For instance , in May 2020, J.K Lon Government Children Hospital (India) launched less invasive surfactant administration treatment (LISA) for neonatal respiratory distress syndrome also to minimize the side effect caused due to long time exposure of ventilators, LISA technique is very useful, where the surfactant is administered via thin feeding tube and removed immediately after the procedure is completed.
In February 2020, Windtree Therapeutics, a clinical-stage, biopharmaceutical and medical device company, initiated a study on efficacy and safety of Lucinactant for inhalation in preterm neonates 26 -32 weeks of age suffering from neonatal respiratory distress syndrome. The study was a multinational, multicenter, double-blind (masked), parallel group, randomized, controlled study, in preterm neonates 26 to 32 completed weeks PMA(Post-menstrual age).
In September 2018, the Catholic University of Sacred Heart completed clinical trial of a new technique called IN-REC-SUR-E, IN-SUR-E alone in spontaneously breathing preterm infants requiring nasal continuous positive airway pressure (nCPAP) as initial respiratory support and reaching pre-defined CPAP failure criteria, in preterm neonates with respiratory distress syndrome. The treatment involves the Proactant Alfa drug, high frequency oscillating ventilator and neonatal continuous positive air pressure nasal cap.

Pulmonary Surfactant Market-Restraints

Increasing number of side effect associated with the pulmonary surfactant drug restrain the growth of pulmonary surfactants market. The drugs used in the treatment of respiratory disorders have several side effects. For instance according to a report published by RxList Inc, an online medical resource offering detailed and current pharmaceutical information on brand and generic drugs, on March 3, 2022, common side effects of Surfaxin, a liquid medication used to treat infant respiratory distress syndrome, are related to its administration down a premature infant's breathing tube (endotracheal tube) and include endotracheal tube reflux, skin paleness, endotracheal tube obstruction, and need for dose ductus arteriosus and lung problems.

Key Players

Key players operating in the global pulmonary surfactant market include Boehinger Ingelheim, AbbVie Inc, Chiesi Farmaceutici, ONY Biotech Inc., Lyomark Pharma, Abbott, Aviva Systems Biology Corporation, Windtree Therapeutics, Inc, Tekzima (Noargen), Biomatik, Nanjing Norris Pharm Technology, Reddot Biotech

Table of Content

Table of Contents

*Browse 39 market data tables and 32 figures on “Global Pulmonary Surfactant Market” - forecast to 2030

Segmentation

Detailed Segmentation:

- Asia Pacific
  - By Type
    - Synthetic Pulmonary Surfactant
    - Animal Derived Surfactant
  - By Drug Type
    - Poractant alfa
    - Lucinactant
    - Calfactant
  - By Indications
    - Respiratory Distress Syndrome (RDS)
    - Respiratory Infections
    - Obstructive lung Diseases
    - Others(chronic lung disease of prematurity, and surfactant protein-B deficiency)
  - By Route of Administration
    - Intratracheal
    - Injectable
  - By Distribution Channel
    - Hospital Pharmacy
    - Retail Pharmacy
    - Online Pharmacy
  - By Country:
    - Australia
    - India
    - China
    - Japan
    - ASEAN
    - South Korea
    - Rest of Asia Pacific
- Middle East
  - By Type
    - Synthetic Pulmonary Surfactant
    - Animal Derived Surfactant
  - By Drug Type
    - Poractant alfa
    - Lucinactant
    - Calfactant
  - By Indications
    - Respiratory Distress Syndrome (RDS)
    - Respiratory Infections
    - Obstructive lung Diseases
    - Others(chronic lung disease of prematurity, and surfactant protein-B deficiency)
  - By Route of Administration
    - Intratracheal
    - Injectable
  - By Distribution Channel
    - Hospital Pharmacy
    - Retail Pharmacy
    - Online Pharmacy
  - By Country:
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Type
    - Synthetic Pulmonary Surfactant
    - Animal Derived Surfactant
  - By Drug Type
    - Poractant alfa
    - Lucinactant
    - Calfactant
  - By Indications
    - Respiratory Distress Syndrome (RDS)
    - Respiratory Infections
    - Obstructive lung Diseases
    - Others(chronic lung disease of prematurity, and surfactant protein-B deficiency)
  - By Route of Administration
    - Intratracheal
    - Injectable
  - By Distribution Channel
    - Hospital Pharmacy
    - Retail Pharmacy
    - Online Pharmacy
  - By Country/Region:
    - South Africa
    - Central Africa
    - North Africa

- Frequently Asked Questions -

What are the growth estimates for global pulmonary surfactant market till 2030?

The global pulmonary surfactant market is estimated to surpass US$ 822.9 million by 2030.

Which are the prominent pulmonary surfactant market players across the globe?

Major players operating in the market include Boehinger Ingelheim, AbbVie Inc, Chiesi Farmaceutici, ONY Biotech Inc., Lyomark Pharma, Abbott, Aviva Systems Biology Corporation, Windtree Therapeutics, Inc, Tekzima (Noargen), Biomatik, Nanjing Norris Pharm Technology, Reddot Biotech

Which segment based on type, accounted for the highest demand in market of pulmonary surfactant in 2022?

Among type, Animal derived surfactant segment generated significant revenue in 2022, owing to increasing preferences for treatment of respiratory distress syndrome.

What are the key factors driving growth of the market?

Increasing preference of animal derived surfactant for the treatment of respiratory distress syndrome is driving the growth of pulmonary surfactant market growth during the forecast period.

What is the Compound Annual Growth Rate (CAGR) of the market till 2030?

The market is estimated to exhibit a CAGR of 4.50% over the forecast period.

Which region is dominating the market growth?

Among regions, North America is expected to witness significant growth over the forecast period, owing to increasing prevalence of respiratory infections in the U.S.